**Supplemental Material 1.** Baseline clinical, laboratory, angiographic and procedural characteristics before and after PSM

|  |  |  |
| --- | --- | --- |
|  | Total study population | Propensity score-matched patients |
| Variables | ACEIs(*n* = 2059) | ARBs(*n* = 873) | p value | ACEIs (*n* = 774) | ARBs (*n* = 774) | p value |
| Age (years) | 62.2 ± 12.4 | 64.4 ± 12.2 | <0.001 | 63.3 ± 12.4 | 64.0 ± 12.2 | 0.279 |
| Men, n (%) | 1609 (78.1) | 634 (72.6) | 0.001 | 580 (74.9) | 572 (73.9) | 0.641 |
| LVEF (%) | 52.4 ± 10.5 | 54.6 ± 10.8 | <0.001 | 53.6 ± 10.7 | 54.1 ± 10.8 | 0.404 |
| BMI (kg/m2) | 24.3 ± 3.1 | 24.2 ±3.2 | 0.575 | 24.3 ± 3.17 | 24.3 ± 3.29 | 0.885 |
| SBP (mmHg) | 131.0 ± 27.2 | 131.3 ± 27.5 |  0.798 | 130.8 ± 26.4 | 131.7 ± 28.0 | 0.484  |
| DBP (mmHg) | 79.6 ± 16.3 | 80.3 ± 16.2 | 0.304 | 79.6 ± 15.2 | 80.5 ± 16.4 | 0.275  |
| STEMI, n (%) | 1281 (62.2) | 478 (54.8) | <0.001 | 441 (57.0) | 448 (57.9) | 0.719 |
| Primary PCI, n (%) | 1237/1281 (96.6) | 465/478 (97.3) |  0.451 | 421/441 (95.5) | 436/448 (97.3) | 0.137 |
| NSTEMI, n (%) | 778 (37.8) | 395 (45.2) | <0.001 | 333 (43.0) | 326 (42.1) | 0.719 |
|  PCI within 24 hours | 675/778 (86.8) | 345/395 (87.3) |  0.727 | 292/333 (87.7) | 282/326 (86.8) | 0.650  |
| Cardiogenic shock, n (%) | 88 (4.3) | 29 (3.3) |  0.257 | 26 (3.4) | 28 (3.6) | 0.782 |
| CPR on admission, n (%) | 68 (3.3) | 45 (5.2) | 0.017 | 38 (4.9) | 37 (4.8) | 0.906 |
| Hypertension, n (%) | 853 (41.4) | 433 (49.6) | <0.001 | 357 (46.1) | 370 (47.8) | 0.508 |
| Dyslipidemia, n (%) | 239 (11.6) | 90 (10.3) |  0.308 | 86 (11.1) | 83 (10.7) | 0.807 |
| Previous MI, n (%) | 39 (1.9) | 31 (3.6) | 0.007 | 20 (2.6) | 23 (3.0) | 0.643 |
| Previous PCI, n (%) | 78 (3.8) | 57 (6.5) |  0.001 | 41 (5.3) | 46 (5.9) | 0.581 |
| Previous CABG, n (%) | 1 (0.0) | 4 (0.5) |  0.030 | 0 (0.0) | 1 (0.1) | 0.317 |
| Previous HF, n (%) | 12 (0.6) | 10(1.1) |  0.157 | 7 (0.9) | 7 (0.9) | 1.000  |
| Previous CVA, n (%) | 94 (4.6) | 45 (5.2) |  0.492 | 34 (4.4) | 35 (4.5) | 0.902 |
| Current smokers, n (%) | 1030 (50.0) | 368 (42.2) | <0.001 | 341 (44.1) | 337 (43.5) | 0.838 |
| Peak CK-MB (mg/dL) | 148.4 ± 217.1 | 129.5 ± 160.5 |  0.020 | 133.9 ± 190.1 | 136.7 ± 166.0 | 0.753  |
| Peak troponin-I (ng/mL) | 49.1 ± 133.7 | 45.5 ± 66.6 | 0.451 | 52.0 ± 200.7 | 48.0 ± 69.0 | 0.597  |
| NT-ProBNP (pg/mL) | 1069.6 ± 2024.4  | 1318.4 ± 2224.3 |  0.003 | 1196.5 ± 2538.4  | 1193.3 ± 1787.2 | 0.977  |
| hs-CRP (mg/dL) | 7.8 ± 32.6 | 11.4 ± 73.6 | 0.066 | 9.5 ± 39.7 | 8.5 ± 24.6 | 0.524 |
| Serum creatinine (mg/L) | 0.99 ± 0.82 | 1.05 ± 1.25 |  0.220 | 1.06 ± 1.19 | 1.02 ± 1.15 | 0.529  |
| eGFR (mL/min/1.73m2) | 89.5 ± 36.7 | 91.8 ± 42.3 |  0.161 | 89.0 ± 32.5 | 90.4 ± 32.1 | 0.378 |
| Blood glucose (mg/dL) | 146.2 ± 44.5 | 145.6 ± 47.4 | 0.754 | 143.9 ± 45.5 | 145.5 ± 46.5 | 0.500  |
| Hemoglobin A1c, % | 5.95 ± 0.21 | 5.96 ± 0.22 | 0.426 |  |  | 0.561 |
| Total cholesterol (mg/dL) | 191.7 ± 42.6 | 187.7 ± 41.7 | 0.019 | 186.2 ± 40.9 | 189.1 ± 41.6 | 0.170 |
| Triglyceride (mg/L) | 135.8 ± 105.1 | 137.4 ± 113.6 | 0.718 | 137.2 ± 123.5 | 135.9 ± 93.3 | 0.815 |
| HDL cholesterol (mg/L) | 44.1 ± 15.9 | 43.5 ± 14.0 | 0.341 | 43.4 ± 11.1 | 44.0 ± 14.3 | 0.359 |
| LDL cholesterol (mg/L) | 122.4 ± 37.1 | 123.0 ± 67.0 |  0.781 | 117.9 ± 34.1 | 121.2 ± 37.2 | 0.074 |
| Discharge medications |  |  |  |  |  |  |
| Aspirin, n (%) | 2048 (99.5) | 870 (99.7) | 0.494 | 772 (99.7) | 771 (99.6) | 0.654 |
| Clopidogrel, n (%) | 1797 (87.3) | 716 (82.0) | <0.001 | 655 (84.6) | 647 (83.6) | 0.578 |
| Ticagrelor, n (%) | 162 (7.9) | 104 (11.9) | <0.001 | 76 (9.8) | 79 (10.2) | 0.799 |
|  Prasugrel, n (%) | 93 (4.5) | 44 (5.0) |  0.539 | 36 (4.7) | 40 (5.2) | 0.638 |
| Cilostazole, n (%) | 406 (19.7) | 160 (18.3) |  0.383 | 144 (18.6) | 145 (18.7) | 0.948 |
|  Beta-blockers, n (%) | 1849 (89.8) | 742 (85.0) | <0.001 | 656 (84.8) | 671 (86.7) | 0.276 |
|  CCBs, n (%) | 88 (4.3) | 59 (6.8) |  0.005 | 47 (6.1) | 43 (5.6) | 0.664 |
|  Lipid lowering agent, n (%) | 1867 (90.7) | 786 (90.0) |  0.589 | 696 (89.9) | 692 (89.4) | 0.738 |
| Angiographic & procedural characteristics |
| Infarct-related artery |  |  |  |  |  |  |
| Left main, n (%) | 17 (0.8) | 19 (2.2) |  0.002 | 7 (0.9) | 7 (0.9) | 1.000 |
|  Left anterior descending, n (%) | 1060 (51.5) | 414 (47.4) |  0.044 | 370 (47.8) | 380 (49.4) | 0.542 |
| Left circumflex, n (%) | 338 (16.4) | 156 (17.9) |  0.320 | 139 (18.0) | 136 (17.6) | 0.842 |
| Right coronary artery, n (%) | 644 (31.3) | 284 (32.5) |  0.504 | 258 (33.3) | 248 (32.0) | 0.588 |
| Treated vessel |  |  |  |  |  |  |
| Left main, n (%) | 39 (1.9) | 33 (3.8) | 0.003 | 19 (2.5) | 20 (2.6) | 0.871 |
|  Left anterior descending, n (%) | 1249 (60.7) | 504 (57.7) |  0.139 | 432 (55.8) | 461 (59.6) | 0.136 |
| Left circumflex, n (%) | 511 (24.8) | 243 (27.8) |  0.087 | 208 (26.9) | 206 (26.6) | 0.909 |
| Right coronary artery, n (%) | 759 (36.9) | 355 (40.7) |  0.052 | 316 (40.8) | 304 (39.3) | 0.534 |
| ACC/AHA lesion type |  |  |  |  |  |  |
| Type B1, n (%) | 287 (13.9) | 111 (12.7) |  0.376 | 104 (13.4) | 104 (13.4) | 1.000 |
| Type B2, n (%) | 599 (29.1) | 359 (41.1) | <0.001 | 300 (38.8) | 297 (37.4) | 0.876 |
| Type C, n (%) | 989 (48.0) | 299 (34.2) | <0.001 | 278 (35.9) | 285 (36.8) | 0.712 |
| Extent of coronary artery disease |  |  |  |  |  |  |
| One-vessel, n (%) | 1058 (51.4) | 489 (56.0) |  0.019 | 443 (57.2) | 445(56.2) | 0.682 |
| Two-vessel, n (%) | 652 (31.7) | 245 (28.1) |  0.214 | 203 (26.2) | 213 (27.5) | 0.566 |
| ≥ Three-vessel, n (%) | 349 (16.9) | 139 (15.9) |  0.494 | 128 (16.5) | 126 (16.3) | 0.891 |
| Drug-eluting stents |  |  |  |  |  |  |
| ZES, n (%) | 707 (34.3) | 299 (34.2) | 0.964 | 283 (36.6) | 269 (34.8) | 0.458 |
| EES, n (%) | 1080 (52.5) | 453 (51.9) | 0.553 | 389 (50.3) | 389 (50.3) | 1.000 |
| BES, n (%) | 272 (13.2) | 121 (13.9) |  0.637 | 96 (12.4) | 108 (14.0) | 0.367 |
| IVUS, n (%) | 494 (24.0) | 213 (24.4) |  0.814 | 192 (24.8) | 185 (23.9) | 0.679 |
| OCT, n (%) | 23 (1.1) | 4 (0.5) |  0.094 | 3 (0.4) | 3 (0.4) | 1.000 |
| FFR, n (%) | 28 (1.4) | 10 (1.1) |  0.639 | 9 (1.2) | 8 (1.0) | 0.807 |
| Stent diameter (mm) | 3.17 ± 0.42 | 3.12 ± 0.42 |  0.007 | 3.12 ± 0.41 | 3.13 ± 0.42 | 0.487 |
| Stent length (mm) | 27.0 ± 10.9 | 26.2 ± 11.2 |  0.065 | 26.0 ± 9.8 | 26.3 ± 11.4 | 0.608 |
| Number of stent | 1.46 ± 0.77 | 1.51 ± 0.81 |  0.136 | 1.47 ± 0.79 | 1.48 ± 0.80 | 0.768 |

Values are mean ± standard deviations or *n* (%). The p values for continuous data obtained from analysis of the independent sample t-test. The p values for categorical data obtained from the chi-square test or Fisher’s exact test.

ACEIs - angiotensin converting enzyme inhibitors; ARBs - angiotensin II type 1 receptor blockers; LVEF - left ventricular ejection fraction; BMI - body mass index; SBP - systolic blood pressure; DBP - diastolic blood pressure; STEMI - ST-segment elevation myocardial infarction; NSTEMI - non-STEMI; CPR - cardiopulmonary resuscitation; MI - myocardial infarction; PCI - percutaneous coronary intervention; CABG - coronary artery bypass graft; HF - heart failure; CVA - cerebrovascular accidents; CK-MB - creatine kinase myocardial band; NT-ProBNP - N-terminal pro-brain natriuretic peptide; hs-CRP - high sensitivity-C-reactive protein; eGFR - estimated glomerular filtration rate; HDL - high-density lipoprotein; LDL - low-density lipoprotein; CCBs - calcium channel blockers; ACC/AHA - American College of Cardiology/American Heart Association; ZES - zotarolimus-eluting stents; EES - everolimus-eluting stents; BES - biolimus-eluting stents; IVUS - intravascular ultrasound; OCT - optical coherence tomography; FFR - fractional flow reserve.